# Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)

> **NCT00100737** · PHASE2 · TERMINATED · sponsor: **Chiron Corporation** · enrollment: 300 (—)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** interleukin-2
- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT00100737
- **Lead sponsor:** Chiron Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 300 (—)
- **Last updated:** 2006-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00100737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00100737, "Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00100737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*